Millions of books in English, Spanish and other languages. Free UK delivery 

menu

0
  • argentina
  • chile
  • colombia
  • españa
  • méxico
  • perú
  • estados unidos
  • internacional
portada Small Cell Lung Cancer: A New Era Is Beginning?
Type
Physical Book
Publisher
Language
Inglés
Pages
150
Format
Hardcover
Dimensions
24.4 x 17.0 x 1.4 cm
Weight
0.53 kg.
ISBN13
9783036523019

Small Cell Lung Cancer: A New Era Is Beginning?

Morabito, Alessandro ; Rolfo, Christian (Author) · Mdpi AG · Hardcover

Small Cell Lung Cancer: A New Era Is Beginning? - Morabito, Alessandro ; Rolfo, Christian

Physical Book

£ 44.27

  • Condition: New
Origin: U.S.A. (Import costs included in the price)
It will be shipped from our warehouse between Thursday, July 25 and Thursday, August 01.
You will receive it anywhere in United Kingdom between 1 and 3 business days after shipment.

Synopsis "Small Cell Lung Cancer: A New Era Is Beginning?"

Small-cell lung cancer (SCLC) is the most aggressive form of lung cancer: No significant progress has been made in finding new treatments for decades and platinum-based chemotherapy has for a long time represented the standard of care. This therapeutic scenario has recently changed, thanks to positive results in terms of improvement of overall survival obtained with a combination of checkpoint inhibitors (atezolizumab or durvalumab) with platinum-etoposide in patients with extensive disease. Moreover, nivolumab and pembrolizumab showed antitumor activity and received U.S. FDA approval as single agents in patients pretreated with platinum-based therapy and at least one other therapy. The improvement in the knowledge of the biology of SCLC has led to the development of new experimental therapies that have shown promising results, including poly (ADP-ribose) polymerase (PARP) inhibitors, anti-Notch ligand Delta-like protein 3 (anti-DLL3), antibody-drug conjugates, and aurora kinase inhibitors. Future challenges are the identification of predictive biomarkers for immunotherapy, the definition of the role of new biological agents, and the improvement of integrated approached for limited disease. This Special Issue will highlight the current state of treatment of extensive SCLC, focusing on the biology of SCLC, immune-checkpoint inhibitors, PARP inhibitors, and novel cytotoxic chemotherapy and radiotherapy techniques.

Customers reviews

More customer reviews
  • 0% (0)
  • 0% (0)
  • 0% (0)
  • 0% (0)
  • 0% (0)

Frequently Asked Questions about the Book

All books in our catalog are Original.
The book is written in English.
The binding of this edition is Hardcover.

Questions and Answers about the Book

Do you have a question about the book? Login to be able to add your own question.

Opinions about Bookdelivery

More customer reviews